NLG-207 is under clinical development by Ellipses Pharma and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect NLG-207’s likelihood of approval (LoA) and phase transition for Epithelial Ovarian Cancer took place on 23 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NLG-207 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
NLG-207 (CRLX-101) is under development for the treatment of solid tumors including epithelial ovarian cancer, peritoneal cancer, fallopian tube cancer, small-cell lung cancer, rectal cancer and metastatic hormone refractory (Castration Resistant, Androgen-Independent) prostate cancer. The drug candidate is administered intravenously. It acts by targeting hypoxia inducible factor 1 (HIF-1) alpha and topoisomerase I. It comprises the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer. The drug candidate is a poly-cyclodextrin-bis-cysteine-PEG3400-camptothecin-conjugate and it is developed based on cyclodextrin nanoparticle technology (CDP) (Cyclosert). It was also under development for the treatment of lymphoma, small cell lung cancer, non-small cell lung cancer, gastric Cancer, esophageal cancer, adenocarcinoma of the gastroesophageal Junction, metastatic triple negative breast cancer and metastatic renal cell carcinoma.
Ellipses Pharma overview
Ellipses Pharma is a drug development company focused on the advancement of innovative cancer treatments through the clinic. The company has developed a technology platform to access best oncology drug assets for further investigation, analysis and clinical development. Ellipses Pharma provides a permanent source of capital for the development of cancer assets and conducts multiple oncology clinical trials in parallel supported by Scientific Affairs Group. The company is building relationships with research institutions, charitable bodies, pharmaceutical, biotechnology companies, and outsourced development providers for delivering more treatment options in oncology. Ellipses Pharma is headquartered in London, England, the UK.
Quick View NLG-207 LOA Data
|Highest Development Stage|